178 related articles for article (PubMed ID: 22802621)
21. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
22. Effects of the cyclin-dependent kinase inhibitor R-roscovitine on eosinophil survival and clearance.
Farahi N; Uller L; Juss JK; Langton AJ; Cowburn AS; Gibson A; Foster MR; Farrow SN; Marco-Casanova P; Sobolewski A; Condliffe AM; Chilvers ER
Clin Exp Allergy; 2011 May; 41(5):673-87. PubMed ID: 21255143
[TBL] [Abstract][Full Text] [Related]
23. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
[TBL] [Abstract][Full Text] [Related]
24. Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1).
Göke R; Barth P; Schmidt A; Samans B; Lankat-Buttgereit B
Am J Physiol Cell Physiol; 2004 Dec; 287(6):C1541-6. PubMed ID: 15317660
[TBL] [Abstract][Full Text] [Related]
25. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
26. The mechanism of Ara-C-induced apoptosis of differentiating cerebellar granule neurons.
Courtney MJ; Coffey ET
Eur J Neurosci; 1999 Mar; 11(3):1073-84. PubMed ID: 10103100
[TBL] [Abstract][Full Text] [Related]
27. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
[TBL] [Abstract][Full Text] [Related]
28. Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9.
Berberich N; Uhl B; Joore J; Schmerwitz UK; Mayer BA; Reichel CA; Krombach F; Zahler S; Vollmar AM; Fürst R
Br J Pharmacol; 2011 Jul; 163(5):1086-98. PubMed ID: 21391976
[TBL] [Abstract][Full Text] [Related]
29. Molecular models of cyclin-dependent kinase 1 complexed with inhibitors.
Canduri F; Uchoa HB; de Azevedo WF
Biochem Biophys Res Commun; 2004 Nov; 324(2):661-6. PubMed ID: 15474478
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Rosato RR; Almenara JA; Maggio SC; Atadja P; Craig R; Vrana J; Dent P; Grant S
Mol Cancer Ther; 2005 Nov; 4(11):1772-85. PubMed ID: 16275999
[TBL] [Abstract][Full Text] [Related]
31. Induction of UGT1A1 and CYP2B6 by an antimitogenic factor in HepG2 cells is mediated through suppression of cyclin-dependent kinase 2 activity: cell cycle-dependent expression.
Sugatani J; Osabe M; Kurosawa M; Kitamura N; Ikari A; Miwa M
Drug Metab Dispos; 2010 Jan; 38(1):177-86. PubMed ID: 19797611
[TBL] [Abstract][Full Text] [Related]
32. Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons.
Monaco EA; Beaman-Hall CM; Mathur A; Vallano ML
Biochem Pharmacol; 2004 May; 67(10):1947-64. PubMed ID: 15130771
[TBL] [Abstract][Full Text] [Related]
33. The cyclin‑dependent kinase pathway involving CDK1 is a potential therapeutic target for cholangiocarcinoma.
Yamamura M; Sato Y; Takahashi K; Sasaki M; Harada K
Oncol Rep; 2020 Jan; 43(1):306-317. PubMed ID: 31746435
[TBL] [Abstract][Full Text] [Related]
34. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
35. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
36. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of autophagy by 3-MA potentiates purvalanol-induced apoptosis in Bax deficient HCT 116 colon cancer cells.
Coker-Gurkan A; Arisan ED; Obakan P; Guvenir E; Unsal NP
Exp Cell Res; 2014 Oct; 328(1):87-98. PubMed ID: 25088259
[TBL] [Abstract][Full Text] [Related]
38. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
39. Cdc2 and Cdk2 kinase activated by transforming growth factor-beta1 trigger apoptosis through the phosphorylation of retinoblastoma protein in FaO hepatoma cells.
Choi KS; Eom YW; Kang Y; Ha MJ; Rhee H; Yoon JW; Kim SJ
J Biol Chem; 1999 Nov; 274(45):31775-83. PubMed ID: 10542199
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.
Koul D; Fu J; Shen R; LaFortune TA; Wang S; Tiao N; Kim YW; Liu JL; Ramnarian D; Yuan Y; Garcia-Echevrria C; Maira SM; Yung WK
Clin Cancer Res; 2012 Jan; 18(1):184-95. PubMed ID: 22065080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
